AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00019747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thalidomide
Description: oral thalidomide 100 mg at bedtime once daily for 4 weeks, then progresses to 200 mg at bedtime for 4 weeks, then progresses to 300 mg at bedtime (maintenance dose).
Study NCT00019747 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy
Description: Initial dose: 100 mg by mouth (po) every bedtime ( Q hs) for four weeks, then progress to 200 mg po Q hs for four weeks, then progress to maintenance dose: 300 mg po Q hs.
Study NCT00019747 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: adjuvant therapy
Description: Initial dose: 100 mg by mouth (po) every bedtime ( Q hs) for four weeks, then progress to 200 mg po Q hs for four weeks, then progress to maintenance dose: 300 mg po Q hs.
Study NCT00019747 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral placebo once daily
Study NCT00743444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3355
Description: 65 mg capsules, oral, 3 single doses
Study NCT00743444 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: capsules, oral, 3 single doses
Study NCT00003005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cordycepin
Description: Dose escalation study using the following doses:~6mg/m2, 12 mg/m2, 24mg/m2, 48mg/m2
Study NCT00003005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deoxycoformycin
Description: Dose escalation using the Fibonacci dose escalation sequence starting dose 2mg/m2, escalating to 3mg/m3 intravenous
Study NCT00310726 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: abrupt weaning at 4 months
Description: abrupt weaning at 4 months
Study NCT00310726 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Continued exclusive breastfeeding
Description: Continued exclusive breastfeeding
Study NCT03168048 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mobile application
Description: Oncologic therapy support by means of a mobile application
Study NCT01426295 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Caphosol
Description: The Caphosol ™ is a recently launched medical in France (2009). (source: laboratory EUSA Pharma ®)~The product is an aqueous solution for mouthwash that comes in the form of a hyper-saturated mixture of calcium phosphate at neutral pH to reconstitute immediately before use.~Each patient randomized to the treatment arms in the study will receive daily at least 4 (maximum 10) mouthwash Caphosol ™.~The treatments are to begin preventive J1 to chemotherapy and continued until out of aplasia (ANC> 500/mm3), and / or mucositis grade 0.
Study NCT01426295 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bicarbonate de sodium
Description: Treatment of the early start on the day of conditioning and stop when the ANC> 500/mm3 and / or mucositis grade zero, provisional date of bone exceeded.~Versylène: Method of administration: gargle made with a minute from 15 to 30 mL, 2-5 times a day, alternating with PAROEX ®.
Study NCT03203538 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LED-light, 1000 lux
Description: Full-spectrum light, 1000 lux, 4000 K. Represent a light intensity within acceptable range (light that is not too glary); 4000 K is among the most commonly used indoor light colour temperatures.
Study NCT03203538 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LED-light, 100 lux
Description: Full-spectrum light, 100 lux, 4000 K. Represent a light intensity within acceptable range (light that provides sufficient eye sight); 4000 K is among the most commonly used indoor light colour temperatures.
Study NCT03203538 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LED-light, 7000 K
Description: Full-spectrum light, 7000 K, 200 lux. Represent the upper border of common colour indoor light temperature, 200 lux is a common indoor light intensity.
Study NCT03993249 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: standard of care chemoradiotherapy + Nivolumab
Study NCT03993249 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: chemoradiotherapy
Description: standard of care chemoradiotherapy
Study NCT03993249 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: chemoradiotherapy
Description: standard of care chemoradiotherapy
Study NCT05362721 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Pressure-volume loop catheter
Description: The cardiac catheterization procedure will be done according to standard protocol as part of the standard clinical care. This has become the standard of care in any patient in which it feasible and is performed with low risk.
Study NCT01797484 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranolazine
Description: Improvement of myocardial microcirculation
Study NCT03452774 — intervention group
Intervention type: OTHER
Intervention: Clinical Trial Matching
Description: Using a proprietary application programming interface (API) linked to existing electronic health records (EHR) platforms, individual clinical data is extracted, analyzed and matched to a parametric database of existing institutional and non-institutional CT. Machine learning algorithms allow for dynamic matching based on CT allocation and availability for optimized matching.
Study NCT03533582 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resection
Description: Undergo surgical resection
Study NCT03203538 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LED-light, 2500 K
Description: Full-spectrum light, 2500 K, 200 lux. Represent the lower border of common colour indoor light temperature, 200 lux is a common indoor light intensity.
Study NCT03203538 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blue LED-light
Description: Blue light with peak wavelength 455 nm. Known to delay the circadian rhythm, suppress melatonin, and increase alertness.
Study NCT03533582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Given PO
Study NCT03533582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV
Study NCT03477604 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MicroStent and Standard PTA
Description: Self-expanding stent and standard PTA balloon
Study NCT03477604 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard PTA
Description: Standard PTA balloon
Study NCT01953328 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Evolocumab
Description: Administered by subcutaneous injection
Study NCT01953328 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Placebo to Evolocumab
Description: Administered by subcutaneous injection
Study NCT00133900 — intervention group
Intervention type: PROCEDURE
Intervention: Phlebotomy
Description: Peripheral blood draws for evaluation of circulating tumor cells
Study NCT03924141 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training in de-escalation
Description: Will receive one hour of de-escalation training
Study NCT01760941 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo standard of care radiation therapy
Study NCT01760941 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: The patient quality of life as measured by the ESAS-r; Edmonton Symptom Assessment System revised.
Study NCT01760941 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: The surveys consists of Radiation Therapy Worthfullness survey; BPI: brief pain inventory; NUS: narcotics usage survey.
Study NCT03062007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI-CON-02
Description: BI-CON-02 prescribed as intravenous infusion once per 3 weeks. Investigational product therapy during 1 year (up to 18 cycles, duration of 21 days each).
Study NCT02867150 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ward Photonics Photonica Professional
Description: Active Device: Ward Photonics, Photonica Professional Red light therapy system~UltraSlim Cold Light® is the name of a patented treatment regimen using the Photonica Professional device for fat removal using LED red light therapy.
Study NCT01136369 — intervention group
Intervention type: DEVICE
Intervention: OSNA Breast Cancer System
Description: For in vitro diagnostic use only.~The OSNA Breast Cancer System is an automated semi-quantitative, in vitro diagnostic test for the rapid detection of greater than (>) 0.2 mm metastases in nodal tissue removed from sentinel lymph node biopsies of breast cancer patients. Results from the assay can be used to guide the intra-operative or post-operative decision to remove additional lymph nodes and to aid in patient staging. An assay positive + or ++ result indicates the presence of metastasis (> 0.2 mm). An assay positive ++ result predicts the presence of macrometastasis (> 2 mm).~Post-operative histological evaluation of permanent sections of the tissue specimen, in accordance with usual diagnostic practice and using the Sysmex lymph node cutting scheme, is required.
Study NCT03203538 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Red LED-light
Description: Red light with peak wavelength 615 nm. Known not to affect the circadian rhythm, melatonin, and alertness.
Study NCT02461836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Protocol: Gemcitabine 1000mg/m2.body surface area (BSA), IV infusion for at least 30 mins, administered at Day1, Day8, Day15)
Study NCT02461836 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: Protocol: 5 Gy/d, for 5 consecutive days
Study NCT02541474 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Integrated care
Description: The PACT model facilitates better care by : 1) a structured person centered needs assessment , 2) individual care plans , and 3) and an inter- professional team that coordinates services across specialties and levels of care.
Study NCT00311181 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantable Cardioverter Defibrillator (ICD), Cardiac Resynchronization Therapy (CRT-D)
Description: Patients that are indicated for an ICD or CRT-D receive one of these devices.
Study NCT01378936 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MI plus IOC group intervention
Description: 45 minute Motivational Interview plus 16 session IOC intervention
Study NCT01378936 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interview only
Description: 45 minute Motivational Interview session
Study NCT01159626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03463275
Description: Oral single 20 mg dose as two 10mg controlled release tablets
Study NCT01159626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03463275
Description: Oral single 40 mg dose as four 10mg controlled release tablets
Study NCT01159626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03463275
Description: Oral single 60 mg dose as six 10mg controlled release tablets
Study NCT01159626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral single dose as matching placebo
Study NCT01159626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03463275
Description: Oral multiple 40 mg doses as four 10mg controlled release tablets for 7 days
Study NCT01159626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral multiple doses as matching placebo for 7 days
Study NCT03120481 — intervention group
Intervention type: OTHER
Intervention: no intervation
Description: no intervention
Study NCT03258047 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: CAR-T
Description: CAR-T is a novel technique for cancer treatent, it includes procedures of modifying patients' T cells outside the body and re-transfuse these cells back into the human body to fight against the cancer cells.
Study NCT02450344 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive health promotion
Description: An Internet quiz game competition utilising quiz questions related to alcohol
Study NCT02450344 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Passive health promotion
Description: An electronic package of information related to alcohol
Study NCT01549756 — intervention group
Intervention type: BEHAVIORAL
Intervention: bulletin board and teleophone depth interview
Description: qualitative based research
Study NCT00807144 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus (Kidney transplant maintenance immunosuppression)
Description: Standard-release Tacrolimus 1 to 20mg daily in two divided doses to maintain trough drug levels 6-9ng/ml
Study NCT02776813 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACTR087
Study NCT02776813 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Study NCT04039919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Padsevonil
Description: Padsevonil will be administered in predefined dosages.
Study NCT02117102 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bladder and lumbar stimulation technic
Study NCT04039919 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Padsevonil
Description: Padsevonil will be administered in predefined dosages.
Study NCT03735732 — intervention group
Intervention type: BEHAVIORAL
Intervention: prime
Description: groups be confronted with health or palatability aspects of food items
Study NCT03585387 — intervention group
Intervention type: PROCEDURE
Intervention: Navigation
Description: Navigation of a balloon catheter using two navigation methods (1-Fluoroscopy only; 2- Fluoroscopy + CPS).
Study NCT01343472 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WISP supervision
Description: WISP entails a warning session (Orientation Hearing) where the rules of parole are laid out and parolees are told that any violation of stated parole conditions will be sanctioned with a brief jail term (typically a few days in jail). WISP includes regular random drug testing.
Study NCT04039919 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (PSL)
Description: Placebo will be provided matching Padsevonil to maintain the blinding.
Study NCT01343472 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Parole-as-usual
Description: Parolees are supervised under standard parole supervision practice in Washington State.
Study NCT02050841 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: octaplas
Description: Octaplas S/D Plasma
Study NCT02865174 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical tranexamic acid
Description: Intraarticular application of tranexamic acid 3g in 100 ml normal saline into knee joint after closure of the joint capsule
Study NCT02865174 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Floseal®
Description: Floseal® (Hemostatic matrix, 10ml, Baxter) was applied on potential bleeding sites: the femoral insertion of the posterior cruciate ligament, the lateral genicular artery after resection of the meniscus, the posterior capsule of the knee joint, the bony surfaces not covered by the implant as well as the pinholes (femur and tibia). The entire content of a 10 mL vial containing the active product (Floseal®) was used. The HM remained in place for 3 minutes and was then gently rinsed from the knee as recommended by the manufacturer (Baxter)
Study NCT02865174 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Enoxaparin
Description: Enoxaparin will be administrated sc 40mg each day postoperatively as venous thromboembolism prophylaxis in the duration of hospital stay
Study NCT02865174 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: Enoxaparin will be administrated sc 40mg each day postoperatively as venous thromboembolism prophylaxis in the duration of hospital stay
Study NCT02590107 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Boost Plus
Description: Receive nutritional supplementation twice daily to provide 28g of protein
Study NCT02590107 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pro-Stat 101
Description: Receive nutritional supplementation twice daily to provide 30g of protein
Study NCT02590107 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Milkshake
Description: Receive alternate nutritional supplementation once daily to provide 28g protein
Study NCT00402220 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TMS
Description: Active Transcranial Magnetic Stimulation
Study NCT00402220 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham TMS
Description: Sham Transcranial Magnetic Stimulation
Study NCT02324673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol Oral Solution
Description: An oral solution containing pharmaceutical grade cannabidiol (nonplant-based).
Study NCT03197558 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: Tymbion Iontophoresis and Tube Delivery System (TDS)
Description: Subjects will receive active Tymbion iontophoresis and tube insertion using the Tube Delivery System in all ears indicated for tube placement.
Study NCT02280226 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: magnetic resonance imaging (MRI)
Study NCT04579315 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intervention group; NNRD group
Description: The intervention is a whole food approach, meaning that the participants in the intervention group receives all daily food elements that they should consume
Study NCT00592202 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Placement of an adjustable gastric band
Description: Laparoscopic placement of an adjustable gastric band around the upper portion of the stomach and subsequent adjustments of the band via a subcutaneous port as needed to maintain appropriate restriction.
Study NCT02590107 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: daily food diaries
Description: Participants will be given a food intake form, clipboard, and pen to record specific foods, as well as amounts of foods that are consumed from outside sources. In addition, the specific food items that each participant consumes will be recorded by the participant on his or her meal tickets which are included with each meal tray
Study NCT04629742 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Seawater Pizza
Description: A seawater pizza administered to 12 healthy subjects
Study NCT04629742 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard pizza
Description: A standard pizza administered to 12 healthy subjects
Study NCT01602016 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Folinic Acid and placebo
Description: Capsules of folinic acid and placebo will be administered in 1mg/kg/day in two divided doses (0.5mg/kg/dose; 25mg/day maximum) for two weeks followed by 2 mg/kg/day with a maximum dose of 50mg/day provided the lower dose is well tolerated for 10 weeks.
Study NCT01602016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folinic Acid
Description: capsules of folinic acis will be provided. The target dose will be 1mg/kg/day in two divided doses (0.5mg/kg/dose; 25mg/day maximum) for two weeks followed by 2 mg/kg/day with a maximum dose of 50mg/day provided the lower dose is well tolerated, for 10 weeks.
Study NCT03870477 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: THP Hip Fracture Plating System with telescoping lag screws
Description: The fracture plates are contoured plates used in conjunction with telescoping lag screws that are 7.5mm in diameter with lengths ranging from 70mm to 130mm in 5mm increments.
Study NCT01010022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6% hydroxyethyl starch 130/0.4
Description: Up to 1000mL 6% hydroxyethyl starch 130/0.4 solution i.v., intra-operatively (from start of surgery until end of surgery)
Study NCT01010022 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 6% hydroxyethyl starch 70/0.5 (Salinhes®)
Description: Up to 1000mL 6% hydroxyethyl starch 70/0.5 (Salinhes®) solution i.v., intra-operatively (from start of surgery until end of surgery)
Study NCT02954159 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Oral tacrolimus tablet starting at 0.05mg/kg twice daily, with dose adjustments aiming for serum trough levels of 10-15 ng/ml during the first 2 weeks, and 5-10ng/ml subsequently.
Study NCT02954159 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vedolizumab
Description: Intravenous Vedolizumab 300 mg at week 0, 2 and 6 followed by the same dose every 8 weeks. This drug will be given as per standard of care.
Study NCT02954159 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vedolizumab
Description: Intravenous Vedolizumab 300 mg at week 0, 2 and 6 followed by the same dose every 8 weeks. This drug will be given as per standard of care.
Study NCT02954159 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will be randomized 1:1 in Treatment arm (receive Tacrolimus) and Placebo Arm.
Study NCT03978845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Using an ultrasound and a nerve stimulator, the phrenic nerve will be identified and low-dose lidocaine will be administered perineurally.